CLGN - CIK 0001631487
CollPlant Biotechnologies Ltd trades as CLGN. In its fiscal 2025 annual report the company posted revenue of $2.37M, up 360.4% from the prior year and net income of -$11.49M. This page tracks CollPlant Biotechnologies Ltd through 317 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 7 fiscal years CollPlant Biotechnologies Ltd's revenue declined from $5.01M to $2.37M, a compound annual decline rate of 10.1%. Net profit margin compressed from -124.6% to -484.6% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| New insider ownership | 3 | 2026-04-27 |
| EFFECT | - | 2026-04-21 |
| 424B3 | - | 2026-04-21 |
| Company correspondence | CORRESP | 2026-04-17 |
| F-1/A | - | 2026-04-15 |
| 6-K | - | 2026-04-13 |
| SEC correspondence | UPLOAD | 2026-04-01 |
| F-1 | - | 2026-03-30 |
The largest companies sharing CollPlant Biotechnologies Ltd's SEC industry classification (orthopedic, prosthetic & surgical appliances & supplies).
CollPlant Biotechnologies Ltd reported revenue of $2.37M for fiscal year 2025, an increase of 360.4% year over year.
In its latest fiscal year CollPlant Biotechnologies Ltd reported a net loss of $11.49M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.